Actinium PharmaceuticalsATNM
ATNM
About: Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Employees: 31
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
1,190% more call options, than puts
Call options by funds: $129K | Put options by funds: $10K
41% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 17
29% more capital invested
Capital invested by funds: $10.2M [Q4 2024] → $13.2M (+$2.95M) [Q1 2025]
22% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 9
1% more funds holding
Funds holding: 69 [Q4 2024] → 70 (+1) [Q1 2025]
0.21% more ownership
Funds ownership: 26.07% [Q4 2024] → 26.28% (+0.21%) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$4
168%
upside
Avg. target
$4
168%
upside
High target
$4
168%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis | 168%upside $4 | Buy Reiterated | 12 May 2025 |
Financial journalist opinion
Based on 89 articles about ATNM published over the past 30 days
Neutral
PRNewsWire
5 days ago
Kuehn Law Encourages Investors of Actinium Pharmaceuticals, Inc. to Contact Law Firm
NEW YORK , June 10, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Actinium Pharmaceuticals, Inc. (NYSE: ATNM) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Actinium Pharmaceuticals caused the company to misrepresent or fail to disclose that (1) the Company's data from the Sierra Trial was unlikely to satisfy the FDA's guidelines for the acceptance and approval of Iomab-B BLA; (2) the additional analyses, including long-term follow-ups that purportedly demonstrated a trend towards improved Overall Survival that the Company provided to the FDA in an attempt to mitigate Sierra's poor OS data were unlikely to satisfy the FDA's guidelines for the acceptance and approval of Iomab-B BLA; (3) as a result, the FDA would likely refuse to review the Iomab-B BLA or, if it did consider that BLA, that the application in its current form was unlikely to be approved; and (4), as a result, positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Neutral
Accesswire
2 weeks ago
Shareholders of Actinium Pharmaceuticals, Inc. (ATNM): Protect Your Rights Before May 27, 2025 - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=150393&wire=1&utm_campaign=21 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
2 weeks ago
Levi & Korsinsky Urges Actinium (ATNM) Shareholders to Act Before Lead Plaintiff Deadline May 27, 2025
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=150356&wire=1&utm_campaign=19 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
2 weeks ago
ATNM DEADLINE TODAY: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Investors to Secure Counsel Before Important May 27 Deadline in Securities Class Action - ATNM
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / Rosen Law Firm: WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) between October 31, 2022 and August 2, 2024, both dates inclusive (the "Class Period"), of the important May 27, 2025 lead plaintiff deadline. SO WHAT: If you purchased Actinium securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Neutral
Accesswire
2 weeks ago
Securities Class Action Lawsuit Filed Against Actinium Pharmaceuticals, Inc. (ATNM) - Levi & Korsinsky Represents Shareholders
NEW YORK, NY / ACCESS Newswire / May 26, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=150273&wire=1&utm_campaign=13 or contact Joseph E. Levi, Esq.
Neutral
GlobeNewsWire
2 weeks ago
ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, May 26, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. (“Actinium” or “the Company”) (NYSE: ATNM) and certain of its officers.
Neutral
Accesswire
2 weeks ago
ATNM LAWSUIT ALERT: Levi & Korsinsky Notifies Actinium Pharmaceuticals, Inc. Investors - Lead Plaintiff Deadline May 27, 2025
NEW YORK, NY / ACCESS Newswire / May 26, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=150254&wire=1&utm_campaign=7 or contact Joseph E. Levi, Esq.
Neutral
Accesswire
2 weeks ago
Lost Money on Actinium Pharmaceuticals, Inc. (ATNM)? Urged to Join Class Action Before May 27, 2025 - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / May 26, 2025 / If you suffered a loss on your Actinium Pharmaceuticals, Inc. (NYSE:ATNM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/actinium-lawsuit-submission-form?prid=150240&wire=1&utm_campaign=22 or contact Joseph E. Levi, Esq.
Neutral
PRNewsWire
2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
NEW YORK , May 26, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company") (NYSE: ATNM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Neutral
PRNewsWire
2 weeks ago
ATNM Deadline: ATNM Investors with Losses in Excess of $100K Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit
NEW YORK , May 26, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) between October 31, 2022 and August 2, 2024, both dates inclusive (the "Class Period"), of the important May 27, 2025 lead plaintiff deadline. So what: If you purchased Actinium securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Charts implemented using Lightweight Charts™